Norwich, Connecticut (PressExposure) August 27, 2009 -- Mystic Management Systems' document control software product ensur was selected by Mersana Therapeutics, Inc. of Cambridge, Massachusetts, for document and version control of their key quality content. Mersana's ensur deployment will be in conjunction with the introduction of a second lead product candidate.
"Mersana's progress in the cancer therapeutics division is globally recognized and being partnered with them in their future success is a tremendous opportunity "said Erica Sullivan-Corbett of Mystic Management Systems, Inc.
The deployment of ensur at Mersana will be validated in line with the FDA's 21CFR Part 11 regulations and will include the installation of the latest 4.0 version of Document Control, Change Control, CAPA, TMS, Quiz Builder, Form Builder, Quality Binder, Bills of Material, Publish, Mail, Reports, Controlled Printing and Watermarking.
About Mersana Therapeutics, Inc.
Named after the Russian goddess of harvest, Mersana's strategy is to identify promising cancer agents that faltered in development despite evidence of clinical efficacy and to bring them to fruition.
Mersana, a privately held, venture backed company, utilizes its proprietary nanotechnology platform to transform existing and experimental anti-cancer agents into new, patentable drugs with superior pharmaceutical properties. The key component of Mersana's platform is FleximerÂ®, a novel, biodegradable and bio-inert polymer that can be chemically linked to small molecules and biologics. Mersana's pipeline includes XMT-1001, a Fleximer-camptothecin conjugate which is currently in Phase 1 clinical trials, and several preclinical oncology compounds. Mersana's investors include Fidelity Biosciences, ProQuest Investments, Rho Ventures, Harris & Harris Group and PureTech Ventures.